Stage 0 hematogones essentially lack CD9 expression: comparative immunophenotypic analysis of hematogone subsets and myeloid blasts
American Journal of Clinical Pathology · 04.11.2026 · 166 (5)
DOI: 10.1093/ajcp/aqag127 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 07.11.2026. Verfasst von Jessica Hughes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, City of Hope Medical Center, Duarte, CA, United States. Hauptthemen laut MEDLINE: Tetraspanin 29, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Myeloid Cells. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objectives
Measurable residual disease (MRD) assessment of B lymphoblastic leukemia (BLL) by flow cytometry (FC) can be confounded by normal populations, particularly stage 0 hematogones (HGs), following CD19-targeted therapy. Few studies have reported expression patterns or compared them with other populations. We assessed expression of CD9, CD34, CD45, CD58, CD66c/CD13/CD33, and CD81 on stage 0 HGs and compared the findings to stage 1 to 3 HGs and myeloid blasts (MBs).
Methods
Cases of BLL MRD FC were reviewed for residual disease, and negative cases with stage 0 HGs were further evaluated for stage 1 to 3 HGs and MBs. Dot plot patterns and median fluorescence intensity (MFI) were evaluated and compared across populations.
Results
Unlike stage 1 to 3 HGs, stage 0 HGs essentially lacked CD9 expression. CD9 MFI on stage 1 to 3 HGs demonstrated a broad range, typically with prominent bright components, although some cases showed significant CD9-negative subsets. Stage 0 HG CD34 was similar to stage 1 and slightly lower than MBs. CD45 expression was similar among stage 0 HGs, stage 1 HGs, and MBs. Although all HG stages appeared overall similar on dot plots, CD58 and CD66c/CD13/CD33 MFIs were higher, and CD81 MFI was lower in stage 0 HGs than in later stages. CD81 expression was higher in all HG stages compared with MBs.
Conclusions
Unlike stage 1 to 3 HGs, stage 0 HGs essentially lack CD9 expression. CD58, CD66c/CD13/CD33, and CD81 may show slight shifts in intensity compared with other stages. These findings should be considered when assessing BLL MRD by FC following CD19-directed therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, City of Hope Medical Center, Duarte, CA, United States.
- Department of Computation and Quantitative Medicine, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, United States.
ORCID-Profile: Joo Song
Zitieren
APA
Hughes, J., Song, J., Ma, H., Lee, W., Gaal, K., Tizro, P., Liu, Y., Quirk, E., & Soma, L. (2026). Stage 0 hematogones essentially lack CD9 expression: comparative immunophenotypic analysis of hematogone subsets and myeloid blasts. American Journal of Clinical Pathology, 166(5). https://doi.org/10.1093/ajcp/aqag127
Vancouver
Hughes J, Song J, Ma H, Lee W, Gaal K, Tizro P, et al. Stage 0 hematogones essentially lack CD9 expression: comparative immunophenotypic analysis of hematogone subsets and myeloid blasts. American Journal of Clinical Pathology. 2026;166(5). doi:10.1093/ajcp/aqag127
BibTeX
@article{Hughes2026,
author = {Hughes, Jessica and Song, Joo and Ma, Huiyan and Lee, Winston and Gaal, Karl and Tizro, Parastou and Liu, Yan and Quirk, Elizabeth and Soma, Lori},
title = {Stage 0 hematogones essentially lack CD9 expression: comparative immunophenotypic analysis of hematogone subsets and myeloid blasts},
journal = {American Journal of Clinical Pathology},
year = {2026},
volume = {166},
number = {5},
doi = {10.1093/ajcp/aqag127}
}
EUVIMED